Carroll Financial Associates’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Carroll Financial Associates’s Portfolio AST Stock Details AST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-5,150	Closed	-$6K	–	1461
2018 Q3	$6K	Hold	5,150	–	–	﹤0.01%	1062
2018 Q2	$6K	Hold	5,150	–	–	﹤0.01%	1033
2018 Q1	$7K	Buy	+5,150	New	+$10.8K	﹤0.01%	952
2017 Q4	–	Sell	-5,150	Closed	-$17K	–	1351
2017 Q3	$17K	Hold	5,150	–	–	﹤0.01%	710
2017 Q2	$18K	Buy	+5,150	New	+$17K	﹤0.01%	711

Other funds holding AST

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

NFC

Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Carroll Financial Associates's AST Position: Q4 2018 in Review

Carroll Financial Associates sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q4 2018, closing a stake of 5,150 shares — an estimated $6K sold.

Carroll Financial Associates first reported a position in AST in Q2 2017 and held it in 5 quarters. The position peaked at $18K in Q2 2017. 46 funds tracked by Wall St. Rank hold AST as of Q4 2018.

Carroll Financial Associates reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q4 2018 after selling out during the quarter.
Carroll Financial Associates sold 5,150 Asterias Biotherapeutics Inc. Series A shares in Q4 2018, an estimated $6K.
Carroll Financial Associates first reported a position in Asterias Biotherapeutics Inc. Series A in Q2 2017 and held it in 5 quarters.
Carroll Financial Associates's Asterias Biotherapeutics Inc. Series A position peaked at $18K in Q2 2017.
46 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q4 2018.

Based on Carroll Financial Associates's 13F filing for Q4 2018, filed 11 Jan 2019.